САКСАГЛИПТИН В КОНЦЕПЦИИ ЭФФЕКТИВНОГО УПРАВЛЕНИЯ САХАРНЫМ ДИАБЕТОМ 2 ТИПА


Цитировать

Полный текст

Аннотация

Эффективное управление сахарным диабетом 2 типа (СД2) является одной из самых актуальных проблем современной диабетологии. Это обусловлено как прогрессирующим характером самого заболевания, так и осложнениями лечения (гипогликемия и увеличение массы тела), которые развиваются на фоне применения ряда пероральных сахароснижающих препаратов и существенно влияют не только на приверженность пациентов с СД2 рекомендованной терапии, но и на риск развития сердечно-сосудистых заболеваний. В связи с этим к современной фармакотерапии СД2 должны предъявляться жесткие требования в отношении не только эффективности, но и безопасности. Этим критериям соответствует препарат саксаглиптин - ингибитор фермента дипептидилпептидазы-4. Саксаглиптин относится к принципиально новой группе сахароснижающих препаратов, глюкозозависимое действие которых основано на эффекте инкретинов. Данные клинических исследований подтвердили эффективность и безопасность применения саксаглиптина у пациентов с СД2 как в качестве монотерапии, так и в комбинации с другими сахароснижающими препаратами.

Об авторах

Нина Александровна Петунина

Первый МГМУ им. И.М. Сеченова, Москва

Первый МГМУ им. И.М. Сеченова, Москва

Анна Викторовна Бращенкова

Первый МГМУ им. И.М. Сеченова, Москва

Первый МГМУ им. И.М. Сеченова, Москва

N A Petunina

A V Brashcenkova

Список литературы

  1. International Diabetes Federation. IDF Diabetes Atlas, 4th ed. Brussels, Belgium: International Diabetes Federation 2009. http://www.idf.org/diabetesatlas, accessed July 6th 2011.
  2. Karam JG, McFarlane SI. Prevention of type 2 DM: implications for adolescents and young adults. Pediatr Endocrinol Rev 2008;5(suppl. 4):980-88.
  3. US Department of Health and Human Services, National Diabetes Information Clearinghouse. National Diabetes Statistics 2007. NIH Publication No. 08-3892. http://diabetes.niddk.nih.gov/dm/pubs/statistics/DM_Statistics.pdf. Last updated: June 2008. Accessed October 19, 2010.
  4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
  5. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290(14):1884-90.
  6. National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
  7. Wolf JL, Starfield B, Anderson G. Prevalence, expenditures and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002;162(20):2269-76.
  8. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157:1681-86.
  9. Elrick H, Stimmler L, Hlad CJ Jr, Rai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.
  10. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-98.
  11. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.
  12. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.
  13. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36.
  14. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003;17:161-71.
  15. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298(2):194-206.
  16. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86(8):3717-23.
  17. Kim YB, Kopcho LM, Kirby MS, et al. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipepti-dyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch Biochem Biophys 2006;445:9-18.
  18. Boulton DW, Geraldes M. Safety, tolerabilty, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects [abstract no. 606-P plus poster]. 67th Scientific Sessions of the American Diabetes Association 2007 Jun. Chicago (IL).
  19. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
  20. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003;163:1306-16.
  21. Monnier L, Lapinski H, Collette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA1C. Diabetes Care 2003;26:881-85.
  22. Ceriello A Bortolotti N, Motz E, et al. Meal induced oxidative stress and low density lipoprotein oxidation in diabetes: the possible role of hyperglycaemia. Metabolism 1999;48:1503-08.
  23. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycaemia rapidly suppresses flow mediated endothelium dependant vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54.
  24. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993;36:1119-25.
  25. Rosenstock J, Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;25(10):2401-11.
  26. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11(6):611-22.
  27. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009;32(9):1649-55.
  28. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonyl-urea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63(9):1395-406.
  29. Allen E, Hollander P, Li J, et al. Saxagliptin added to a thiazolidinedione improves glycaemic control in patients with inadequately controlled type 2 diabetes [abstract no. 859]. Diabetologia 2008;51(suppl. 1):342-43.
  30. Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян Г.Р., Майоров А.Ю., Мкртумян А.М., Петунина Н.А., Сухарева О.Ю. Проект "Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа" // Сахарный диабет. 2011. № 1. С. 95-105.
  31. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009;31(11):2608-17.
  32. Boulton D, Tang A, Patel C, et al. Pharmacokinetics of dipeptidylpepetidase-4 inhibitor saxagliptin in subjects with renal impairment (abstract no. P.357). Istanbul. 11th European Congress of Endocrinology 2009 Apr; 25-9.
  33. Nowicki M, et al. Saxagliptin improves glycemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment compared with placebo. Diabetes Obes Metab 2011;13(6):523-32.
  34. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123(5):1705-25.
  35. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. C M A J 2005;172(7):899-905.
  36. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
  37. Patel C, Castaneda L, Frevert U, et al. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects. Diabetes 2008;57(suppl. 1):A160.
  38. Cook MN, et al. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med 2007;24:350-58.
  39. Rosenstock J, Gross J, Salinas C, et al. Long-Term Safety and Efficacy of Saxagliptin After 4-Year Follow-Up of Patients With Type 2 Diabetes. ADA 2011;1086.
  40. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94.
  41. Lenhard JM, Croom DK, Minnick DT, et al. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Comm 2004;324:92-7.
  42. Duckworth W, Abraira C, Moritz T, et al. Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39.
  43. Göke B, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;64(12):1619-31.
  44. Göke B, et al. Saxagliptin vs Glipizide as Add-On Therapy to Metformin for Type 2 Diabetes Mellitus (T2DM): Long-Term Safety and Efficacy. ADA 2011;1110.
  45. Boulton DW, Goyal A, Li L, et al. The effects of age and gender on the single-dose pharmacokinetics and safety of saxagliptin in healthy subjects [abstract no. P.551]. Diabetes 2008;57 (Suppl. 1):A164.
  46. Maheux P, et al. Efficacy and Safety of Saxagliptin 5 mg Once-Daily Therapy in Elderly Patients with Type 2 Diabetes Mellitus. Diabetologia 2009;52(suppl. 1):302.
  47. Frederich R, Fiedorek F, Wolf R, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122(3):16-27.
  48. Bristol-Myers Squibb, AstraZeneca. Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes. March 2010;(press release);http://www.news-medical.net/news/20100310/Bristol-Myers-Squibb-AstraZeneca-commence-SAVOR-TIMI-53-trial-of-ONGLYZA-for-type-2-diabetes.aspx.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2011

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах